about
Acute graft-versus-host disease: a bench-to-bedside update.Prognostic value of response after upfront therapy for acute GVHDEtanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Graft-versus-host disease treatment: predictors of survival.Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure.Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantationA prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre studySteroid-Refractory Acute GVHD: Predictors and Outcomes.Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patientsEfficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Plasma biomarkers of lower gastrointestinal and liver acute GVHD.Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.Advances in understanding the pathogenesis of graft-versus-host disease.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score.Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortalityAdvances in the treatment of acute graft-versus-host disease.Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathSix-month freedom from treatment failure is an important end point for acute GVHD clinical trialsPentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.Assessing response of therapy for acute and chronic graft-versus-host disease.Thinking out of the box--new approaches to controlling GVHD.Next generation treatment of acute graft-versus-host disease.Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs.A risk-adapted approach to acute GVHD treatment: are we there yet?Upper GI GVHD: similar outcomes to other grade II graft-versus-host disease.Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.The association of histologic grade with acute graft-versus-host disease response and outcomes.The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation.Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity.
P2860
Q27687130-829B92DA-1DA2-40B6-BDC6-D13DC5C24BF8Q33964701-0FF2AA78-BA05-4C8E-AAA4-97A47DCF35BBQ34093615-86CA15E5-2734-4CA7-96E3-B1B0BD46FF82Q34205096-C0339DB1-24C6-44C0-AFF3-38384D628DA6Q34463636-4E6CE30C-71B7-457B-B7A7-74909C2E3B15Q34626032-EA683C7E-26BE-4EF6-8B62-D6BD738F461EQ35120338-6CCB5A2F-E17C-4EF9-B890-049FA923B24FQ35550596-E0421B36-A705-47D9-B05E-B36623F2D683Q35588944-A7B29F1F-38E6-4D26-9CAD-9CEF39E07A07Q35623673-558C4C6D-D790-4F0B-80AF-E53CC107059FQ35669073-09C4C04C-A31D-4C8A-8BBB-F5919D06C1E4Q35760517-D48196D9-14A2-48AB-8903-E4833BDFFC1AQ35891657-FC4CF8AB-2D53-44C4-BF2C-5DAA780E553CQ35909700-6059DFE7-2099-46B4-9173-B1A76DF51B82Q35971439-DF405777-BC07-4703-A9B5-C23312D8C3FAQ36113205-41694530-8670-4D26-A5EF-390C33353374Q36846650-192A2504-0555-4640-8711-FAC74644C8DAQ36862931-8EA1740E-4B1E-4262-8F27-A4C663F5C6CFQ37035815-9386B0A9-80F7-43B6-9C10-C54410383318Q37113096-22CC2BD3-B688-42B9-A226-B4C619CFD497Q37191057-68423C87-A5F0-4800-B053-CEB230D1D7E7Q37552088-69C737FC-3B16-43F1-8187-DF100DB6F2FBQ37618997-29EF42E0-BD09-4852-A68F-DFEFEDF19CCFQ37624271-3F876E6A-1EE1-459E-B615-75698DC93942Q37696092-3FE09E7D-D52D-4BBA-A282-33469C22BC78Q37810286-7B0BBC1F-B766-4D22-8AD6-CFC70D609797Q38078431-36F3EDEE-599D-4DE5-94C5-B060DDE58569Q38175862-110B9196-147E-4BE0-AB19-B67EC3B2728FQ38221028-9543F8C3-870B-43F8-8567-EEAE688E5B27Q38416371-5D977BCC-1261-4366-B8FD-25635F04D7FEQ38453666-46592D4F-3D70-468F-B4A7-DA58A0BAEA82Q38628944-4E61CFCD-908F-4599-B690-FE07C63F47F7Q38786092-0EAFE5E6-137F-4B8B-A8D6-558643E0122BQ38839140-39C5AF42-5D5D-406E-B887-A40FA4888E60Q38855365-5A3659F7-9145-4CD7-8FD1-869E23F572C5Q39012031-A8DABDD3-568A-4079-BDF5-B5D05ACE039FQ39168852-4D0EA948-ACDD-4241-A01E-37E4593C1C66Q40148308-69C9225B-AFDC-42E7-BDD6-9033EE9A6BCFQ41121054-5841D7E6-6CA4-4F99-9589-380D5581C19CQ41916538-1FFC8E1C-EA78-4DED-A397-9FBB308AE672
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The best endpoint for acute GVHD treatment trials.
@en
The best endpoint for acute GVHD treatment trials.
@nl
type
label
The best endpoint for acute GVHD treatment trials.
@en
The best endpoint for acute GVHD treatment trials.
@nl
prefLabel
The best endpoint for acute GVHD treatment trials.
@en
The best endpoint for acute GVHD treatment trials.
@nl
P2093
P1433
P1476
The best endpoint for acute GVHD treatment trials.
@en
P2093
Daniel J Weisdorf
Margaret L MacMillan
Todd E DeFor
P304
P356
10.1182/BLOOD-2009-12-258442
P407
P577
2010-04-13T00:00:00Z